GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy designed to mimic the mechanisms of metabolic surgery -  without altering the anatomy. EndoBarrier is approved and commercially available in multiple countries outside the U.S. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts, with offices in Europe and Australia.

Through its patented EndoBarrier® Therapy, GI Dynamics is poised to address the growing diabetes and obesity patient populations, which have reached epidemic proportions and represent two of the largest healthcare markets globally.